Responsiveness and interpretation of a quality of life questionnaire specific to upper gastrointestinal disorders

Christine De La Loge, Elyse Trudeau, Patrick Marquis, Dennis A. Revicki, Anne M. Rentz, Vincenzo Stanghellini, Nicholas J. Talley, Peter Kahrilas, Jan Tack, Dominique Dubois

Research output: Contribution to journalArticlepeer-review

45 Scopus citations

Abstract

Background & Aims: The Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life (PAGI-QOL) has been developed and validated to assess quality of life in gastroesophageal reflux disease, dyspepsia, and gastroparesis. The aim of this work was to assess responsiveness of the PAGI-QOL to clinical changes and provide guidance for the interpretation of score changes. Methods: The analysis was based on 2 observational multicenter, longitudinal, 8-week observation studies, one in the United States and one in 5 European countries. The Overall Treatment Effect scale completed by patients and clinicians at 8 weeks was used to define groups of improved, worsened, and stable patients. Responsiveness was assessed by describing the change in PAGI-QOL scores for each of these groups, comparing these changes over time, and calculating effect sizes and standardized response means. These data were used to define the minimal clinically important difference. Results: A total of 1736 patients with upper gastrointestinal disorders were analyzed. High sensitivity to change over time was demonstrated, with effect sizes and standardized response means in improved patients for the PAGI-QOL total score ranging from 0.79-1.41. A change of 0.4 for the PAGI-QOL total score might be considered as the minimal clinically important difference when comparing pretreatment and post-treatment PAGI-QOL total scores. Conclusions: The PAGI-QOL questionnaire is a responsive and clinically relevant instrument for assessing quality of life in patients with upper gastrointestinal disorders.

Original languageEnglish (US)
Pages (from-to)778-786
Number of pages9
JournalClinical Gastroenterology and Hepatology
Volume2
Issue number9
DOIs
StatePublished - Sep 2004

Funding

Supported by Johnson & Johnson Pharmaceutical Services, LLC.

Keywords

  • ES
  • GERD
  • HRQoL
  • MID
  • OTE
  • Overall Treatment Effect
  • PAGI-QOL
  • Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life instrument
  • effect sizes
  • gastroesophageal reflux disease
  • health-related quality of life
  • minimal important difference

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Fingerprint

Dive into the research topics of 'Responsiveness and interpretation of a quality of life questionnaire specific to upper gastrointestinal disorders'. Together they form a unique fingerprint.

Cite this